ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0588

Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry

Augustine Jose1, Aishwarya Gopal1, Mamatha Gorijavolu1, Anna C Das2, Jagan Babu K L1, Amrita Nayak1, Chengappa Kavadichanda1 and Molly Mary Thabah1, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 2St.Johns National Academy of Health Sciences, Bengaluru, India

Meeting: ACR Convergence 2023

Keywords: B-Cell Targets, Biologicals, Infection, registry, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0582–0608) SLE – Treatment Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rituximab (RTX) is increasingly being employed to treat refractory systemic lupus erythematosus(SLE). Though the drug is effective there is a high risk of adverse events including infections. Most studies have focused on short term(< 1 year) safety, whereas long term follow-up data is sparse. This study was designed to look at the frequency and predictors of infections in patients with SLE receiving RTX who are on long term follow up.

Methods: This was a single-centre retrospective observational study. Data of SLE patients who received at least 1 gram of RTX were abstracted from the case record forms of the department’s biologic registry. Patients were followed up at 3-6 monthly intervals and disease activity, infectious and non-infectious adverse events during or after RTX induction were documented. For those patients who did not have follow up for ≥ 1 year, the last available date of follow-up was considered for this study. Demographic, baseline organ involvement, laboratory data, treatment details were collected. Glucocorticoid exposure was assessed in terms of cumulative steroid (prednisolone) dose, standardized steroid dose (glucocorticoid intake per month of exposure) and number of times the patient received pulse IV methylprednisolone. A ‘serious adverse event’ was defined according to guidelines by International Council on Harmonisation (ICH) 1994. The primary outcome was the occurrence of a serious infection. Secondary outcomes included mortality, time to first serious infection, minor infections and other adverse events.

Results: A total of 76 SLE patients (median age 29 years, 83% females) were included. The median follow-up duration was 27.0 (10-49) months amounting to 177.33 person-years of follow-up. Baseline data of the patients is represented in table 1. Forty-five patients (59.2%) had at least one adverse event. Among these, non-infectious events occurred in 4 (5.26%). Infusion reactions occurred 3 (3.9%), one requiring discontinuation of therapy. One patient had worsening of pre-existing pulmonary artery hypertension. There were 43 (56.6%) patients who had infectious events, 16 of 76 (21.05%) were serious infections amounting to 9.02 infections per 100 person-years of follow-up. Majority(53%) of infections occurred after 1 year of RTX infusion. Site of infections and microrganisms implicated are detailed in table 2. There were total 8 deaths resulting in a mortality rate of 4.5 per 100 person-years of follow-up. All deaths except one were due to serious infection. Male sex, younger patients, CKD, previous cyclophosphamide use, higher cumulative dose of cyclophosphamide, refractory lupus nephritis, higher SLICC ACR damage index at baseline was associated with serious infections (table 1). On binary logistic regression younger age(B 95% CI) and presence of disease damage(B 95% CI) emerged as significant predictors of serious infections (table 3).

Conclusion: Serious infections following RTX are common and result in mortality in SLE. More than 50% of them occur after 1 year of RTX administration. Infections arise from common and rare opportunistic organisms. Juvenile lupus and presence of damage at baseline predispose to infections.

Supporting image 1

Table 1: Baseline demographic and clinical details of the cohort and comparison of patient
groups with and without serious infection

Supporting image 2

Table 2: Infectious complications and outcomes of patients with SLE who received RTX

Supporting image 3

Table 3: Binary logistic regression analysis for predictors of serious infection


Disclosures: A. Jose: None; A. Gopal: None; M. Gorijavolu: None; A. C Das: None; J. Babu K L: None; A. Nayak: None; C. Kavadichanda: None; M. Mary Thabah: None.

To cite this abstract in AMA style:

Jose A, Gopal A, Gorijavolu M, C Das A, Babu K L J, Nayak A, Kavadichanda C, Mary Thabah M. Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/long-term-safety-and-predictors-of-serious-infections-among-patients-with-systemic-lupus-erythematosus-treated-with-rituximab-audit-from-a-single-center-biologic-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-safety-and-predictors-of-serious-infections-among-patients-with-systemic-lupus-erythematosus-treated-with-rituximab-audit-from-a-single-center-biologic-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology